| __timestamp | Alnylam Pharmaceuticals, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 189101000 |
| Thursday, January 1, 2015 | 276495000 | 96351000 |
| Friday, January 1, 2016 | 382392000 | 95967000 |
| Sunday, January 1, 2017 | 390635000 | 112171000 |
| Monday, January 1, 2018 | 505420000 | 182257000 |
| Tuesday, January 1, 2019 | 655114000 | 336964000 |
| Wednesday, January 1, 2020 | 654819000 | 547851000 |
| Friday, January 1, 2021 | 792156000 | 693716000 |
| Saturday, January 1, 2022 | 883015000 | 891813000 |
| Sunday, January 1, 2023 | 1004415000 | 1044071000 |
| Monday, January 1, 2024 | 1126232000 | 910408000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. and Exelixis, Inc. have been at the forefront, investing heavily in R&D to drive breakthroughs. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, reflecting its commitment to pioneering RNA interference therapies. Meanwhile, Exelixis, known for its cancer treatments, increased its R&D spending by more than 450%, underscoring its focus on expanding its oncology pipeline.
In 2023, both companies reached a milestone, with R&D expenses exceeding $1 billion each, a testament to their relentless pursuit of innovation. This trend highlights the critical role of sustained investment in R&D for biotech companies aiming to lead in therapeutic advancements. As these companies continue to push boundaries, their R&D strategies will be pivotal in shaping the future of medicine.
Research and Development: Comparing Key Metrics for Amgen Inc. and Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Lantheus Holdings, Inc.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Ascendis Pharma A/S
R&D Insights: How Exelixis, Inc. and CymaBay Therapeutics, Inc. Allocate Funds
Exelixis, Inc. or Corcept Therapeutics Incorporated: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Research and Development Investment: Exelixis, Inc. vs Alkermes plc
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds